Artelo Biosciences says Phase 1 study shows FABP5 inhibitor ART26.12 is well tolerated, with linear pharmacokinetics

Artelo Biosciences Inc

ARTL

0.00

Artelo Biosciences presented first-in-human Phase 1 results for ART26.12 at the ICRS 2026 Annual Symposium.
The trial showed ART26.12 was generally well tolerated in healthy volunteers, supporting continued clinical development as a non-opioid pain candidate.
Separate biomarker analyses were also presented, flagging treatment-related molecular changes consistent with FABP5 target engagement in humans.
The readout strengthens the company’s case to advance ART26.12 into later-stage studies, also informing follow-on FABP5 inhibitors for indications beyond pain.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Artelo Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606290845PRIMZONEFULLFEED9753976) on June 29, 2026, and is solely responsible for the information contained therein.

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.